JP2017535510A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017535510A5 JP2017535510A5 JP2016551318A JP2016551318A JP2017535510A5 JP 2017535510 A5 JP2017535510 A5 JP 2017535510A5 JP 2016551318 A JP2016551318 A JP 2016551318A JP 2016551318 A JP2016551318 A JP 2016551318A JP 2017535510 A5 JP2017535510 A5 JP 2017535510A5
- Authority
- JP
- Japan
- Prior art keywords
- degrees
- polymorph
- diffraction pattern
- powder
- ray diffraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000634 powder X-ray diffraction Methods 0.000 claims 13
- 229950008006 ferric maltol Drugs 0.000 claims 8
- AHPWLYJHTFAWKI-UHFFFAOYSA-K iron(3+);2-methyl-4-oxopyran-3-olate Chemical compound [Fe+3].CC=1OC=CC(=O)C=1[O-].CC=1OC=CC(=O)C=1[O-].CC=1OC=CC(=O)C=1[O-] AHPWLYJHTFAWKI-UHFFFAOYSA-K 0.000 claims 8
- 239000013078 crystal Substances 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 4
- HYMLWHLQFGRFIY-UHFFFAOYSA-N Maltol Natural products CC1OC=CC(=O)C1=O HYMLWHLQFGRFIY-UHFFFAOYSA-N 0.000 claims 2
- XPCTZQVDEJYUGT-UHFFFAOYSA-N allomaltol Natural products CC=1OC=CC(=O)C=1O XPCTZQVDEJYUGT-UHFFFAOYSA-N 0.000 claims 2
- 229960002413 ferric citrate Drugs 0.000 claims 2
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 claims 2
- 229940043353 maltol Drugs 0.000 claims 2
- -1 maltol anion Chemical class 0.000 claims 2
- 206010022971 Iron Deficiencies Diseases 0.000 claims 1
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1419174.6 | 2014-10-28 | ||
| GB1419174.6A GB2531742B (en) | 2014-10-28 | 2014-10-28 | Polymorphs of ferric maltol |
| PCT/EP2015/074653 WO2016066555A1 (en) | 2014-10-28 | 2015-10-23 | Crystalline forms of ferric maltol |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018169541A Division JP6678711B2 (ja) | 2014-10-28 | 2018-09-11 | マルトール第二鉄の結晶形態 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017535510A JP2017535510A (ja) | 2017-11-30 |
| JP2017535510A5 true JP2017535510A5 (enExample) | 2018-04-05 |
| JP6404358B2 JP6404358B2 (ja) | 2018-10-10 |
Family
ID=52103522
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016551318A Active JP6404358B2 (ja) | 2014-10-28 | 2015-10-23 | マルトール第二鉄の結晶形態 |
| JP2018169541A Active JP6678711B2 (ja) | 2014-10-28 | 2018-09-11 | マルトール第二鉄の結晶形態 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018169541A Active JP6678711B2 (ja) | 2014-10-28 | 2018-09-11 | マルトール第二鉄の結晶形態 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US9802973B2 (enExample) |
| EP (1) | EP3160951B1 (enExample) |
| JP (2) | JP6404358B2 (enExample) |
| KR (1) | KR102576930B1 (enExample) |
| CN (1) | CN107001310B (enExample) |
| AU (1) | AU2015340825B2 (enExample) |
| CA (1) | CA2944210C (enExample) |
| CL (1) | CL2017001030A1 (enExample) |
| EA (1) | EA033323B1 (enExample) |
| ES (1) | ES2661944T3 (enExample) |
| GB (1) | GB2531742B (enExample) |
| IL (1) | IL251863A0 (enExample) |
| MX (1) | MX370730B (enExample) |
| PL (1) | PL3160951T3 (enExample) |
| SA (1) | SA517381406B1 (enExample) |
| SG (1) | SG11201702639RA (enExample) |
| WO (1) | WO2016066555A1 (enExample) |
| ZA (1) | ZA201702136B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2531742B (en) | 2014-10-28 | 2016-10-05 | Iron Therapeutics Holdings Ag | Polymorphs of ferric maltol |
| CN112574158B (zh) * | 2020-12-29 | 2022-08-02 | 南京百泽医药科技有限公司 | 一种麦芽酚铁晶型ii及其制备方法 |
| IT202100018578A1 (it) | 2021-07-14 | 2023-01-14 | Indena Spa | Dispersione amorfa di maltolo ferrico e relativo processo di preparazione |
| AU2022349859A1 (en) * | 2021-09-21 | 2024-05-02 | Apicore Pharmaceuticals Private Limited | An improved process for the preparation of ferric maltol |
| CN119638662B (zh) * | 2024-12-09 | 2025-11-14 | 金陵药业股份有限公司 | 一种麦芽酚铁-草酸共晶及其制备方法 |
| CN119638661B (zh) * | 2024-12-09 | 2025-11-14 | 金陵药业股份有限公司 | 一种麦芽酚铁-槲皮素共晶及其制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE37534E1 (en) | 1982-10-22 | 2002-01-29 | Btg International Limited | Pharmaceutical compositions |
| EP0107458B1 (en) | 1982-10-22 | 1987-07-29 | National Research Development Corporation | Pharmaceutical compositions |
| GB8410290D0 (en) * | 1984-04-19 | 1984-05-31 | Callingham B A | Pharmaceutical compositions |
| GB0211500D0 (en) * | 2002-05-18 | 2002-06-26 | Vitra Pharmaceuticals Ltd | Method of forming iron hydroxypyrone compounds |
| GB201101370D0 (en) * | 2011-01-27 | 2011-03-09 | Iron Therapeutics Holdings Ag | Process |
| WO2014165607A2 (en) * | 2013-04-02 | 2014-10-09 | Stealth Peptides International, Inc. | Aromatic-cationic peptide formulations, compositions and methods of use |
| GB2531742B (en) | 2014-10-28 | 2016-10-05 | Iron Therapeutics Holdings Ag | Polymorphs of ferric maltol |
-
2014
- 2014-10-28 GB GB1419174.6A patent/GB2531742B/en active Active
-
2015
- 2015-10-23 SG SG11201702639RA patent/SG11201702639RA/en unknown
- 2015-10-23 US US15/039,943 patent/US9802973B2/en active Active
- 2015-10-23 ES ES15784705.4T patent/ES2661944T3/es active Active
- 2015-10-23 JP JP2016551318A patent/JP6404358B2/ja active Active
- 2015-10-23 MX MX2017005413A patent/MX370730B/es active IP Right Grant
- 2015-10-23 AU AU2015340825A patent/AU2015340825B2/en active Active
- 2015-10-23 CA CA2944210A patent/CA2944210C/en active Active
- 2015-10-23 EA EA201790667A patent/EA033323B1/ru not_active IP Right Cessation
- 2015-10-23 KR KR1020167024732A patent/KR102576930B1/ko active Active
- 2015-10-23 EP EP15784705.4A patent/EP3160951B1/en active Active
- 2015-10-23 PL PL15784705T patent/PL3160951T3/pl unknown
- 2015-10-23 CN CN201580052331.2A patent/CN107001310B/zh active Active
- 2015-10-23 WO PCT/EP2015/074653 patent/WO2016066555A1/en not_active Ceased
-
2017
- 2017-03-27 ZA ZA2017/02136A patent/ZA201702136B/en unknown
- 2017-04-23 IL IL251863A patent/IL251863A0/en unknown
- 2017-04-25 SA SA517381406A patent/SA517381406B1/ar unknown
- 2017-04-26 CL CL2017001030A patent/CL2017001030A1/es unknown
-
2018
- 2018-09-11 JP JP2018169541A patent/JP6678711B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017535510A5 (enExample) | ||
| JP2018024682A5 (enExample) | ||
| HRP20171151T1 (hr) | Inhibitori cdc7 | |
| NZ742200A (en) | Treatment of osteoarthritis | |
| WO2016014927A3 (en) | Crystalline form of nicotinamide riboside | |
| WO2016134301A3 (en) | Neuroactive steroids, compositions, and uses thereof | |
| JP2019524883A5 (enExample) | ||
| JP2014506907A5 (enExample) | ||
| CN107427516B8 (zh) | 7-苄基-4-(2-甲基苄基)-2,4,6,7,8,9-六氢咪唑并[1,2-a]吡啶并[3,4-e]嘧啶-5(1h)-酮、其类似物、及其盐、以及它们用于治疗的方法 | |
| TN2017000521A1 (en) | New aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| TN2017000511A1 (en) | New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them. | |
| JP2017514910A5 (enExample) | ||
| JP2015500331A5 (enExample) | ||
| WO2013188283A8 (en) | Topical ophthalmological pharmaceutical composition containing sunitinib | |
| HK1207860A1 (en) | 2-phenyl-5-heterocyclyl-tetrahydro-2h-pyran-3-amine compounds for use in the treatment of diabetes and its associated disorders | |
| CA2920410C (en) | Thienopiperidine derivative and use thereof | |
| JP2016537382A5 (enExample) | ||
| EP4582424A3 (en) | 1,2-naphthoquinone derivative and method for preparing same | |
| JP2015522037A5 (enExample) | ||
| IL276194B2 (en) | Pharmaceutical compounds or preparations containing them for use in the treatment of pain | |
| PH12018501292A1 (en) | Pharmaceutical compositions comprising phenylaminopyridine derviative | |
| JP2015516425A5 (enExample) | ||
| HK1212688A1 (zh) | 吡啶酮衍生物及其在治疗、改善或预防病毒疾病中的用途 | |
| JP2014530181A5 (enExample) | ||
| JP2016515550A5 (enExample) |